AU2012280267B2 - Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof - Google Patents

Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof Download PDF

Info

Publication number
AU2012280267B2
AU2012280267B2 AU2012280267A AU2012280267A AU2012280267B2 AU 2012280267 B2 AU2012280267 B2 AU 2012280267B2 AU 2012280267 A AU2012280267 A AU 2012280267A AU 2012280267 A AU2012280267 A AU 2012280267A AU 2012280267 B2 AU2012280267 B2 AU 2012280267B2
Authority
AU
Australia
Prior art keywords
csf
sequence
antibody specific
region
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012280267A
Other languages
English (en)
Other versions
AU2012280267A1 (en
Inventor
Stefan Steidl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys GmbH
Original Assignee
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH filed Critical Morphosys GmbH
Publication of AU2012280267A1 publication Critical patent/AU2012280267A1/en
Priority to AU2016201736A priority Critical patent/AU2016201736A1/en
Application granted granted Critical
Publication of AU2012280267B2 publication Critical patent/AU2012280267B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
AU2012280267A 2011-07-06 2012-07-06 Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof Ceased AU2012280267B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016201736A AU2016201736A1 (en) 2011-07-06 2016-03-18 Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161504744P 2011-07-06 2011-07-06
EP11172865 2011-07-06
US61/504,744 2011-07-06
EP11172865.5 2011-07-06
PCT/EP2012/063207 WO2013004806A1 (en) 2011-07-06 2012-07-06 Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016201736A Division AU2016201736A1 (en) 2011-07-06 2016-03-18 Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2012280267A1 AU2012280267A1 (en) 2014-01-16
AU2012280267B2 true AU2012280267B2 (en) 2016-04-21

Family

ID=47436548

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012280267A Ceased AU2012280267B2 (en) 2011-07-06 2012-07-06 Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
AU2016201736A Abandoned AU2016201736A1 (en) 2011-07-06 2016-03-18 Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016201736A Abandoned AU2016201736A1 (en) 2011-07-06 2016-03-18 Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof

Country Status (10)

Country Link
US (1) US20140234298A1 (enExample)
EP (1) EP2729498A1 (enExample)
JP (1) JP2014520784A (enExample)
KR (1) KR20140061379A (enExample)
CN (1) CN103827143A (enExample)
AU (2) AU2012280267B2 (enExample)
BR (1) BR112013033944A2 (enExample)
CA (1) CA2839513A1 (enExample)
RU (1) RU2013156435A (enExample)
WO (1) WO2013004806A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104995210A (zh) 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
WO2016079276A1 (en) * 2014-11-21 2016-05-26 Takeda Gmbh Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease
CN107847592B (zh) * 2015-06-24 2022-01-21 豪夫迈·罗氏有限公司 用于在淋巴瘤或白血病中诱导淋巴细胞增多的针对人csf-1r的抗体
EP3108897A1 (en) * 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
US20190218284A1 (en) * 2016-09-01 2019-07-18 The Regents Of The University Of Colorado A Body Corporate Methods of treating eosinophilic gastrointestinal diseases
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
CN111757744A (zh) 2017-10-02 2020-10-09 人源股份有限公司 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN112805301B (zh) * 2018-10-15 2023-07-21 安立玺荣生医(香港)有限公司 粒细胞-巨噬细胞集落刺激因子的抗体及其用途
US12624086B2 (en) * 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US20220010007A1 (en) * 2018-11-09 2022-01-13 Kiniksa Pharmaeuticals, Ltd. Treatment for Giant Cell Arteritis
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2020219928A1 (en) * 2019-04-25 2020-10-29 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
KR20230095983A (ko) * 2020-10-26 2023-06-29 키닉사 파마슈티컬스, 리미티드 Gm-csf 길항제를 사용한 암의 치료
EP4328243A4 (en) * 2021-04-20 2025-05-21 Korea University Research and Business Foundation Asymmetric antibody with improved cytotoxicity against cancer cell

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
WO2007092939A2 (en) * 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
WO2008064321A2 (en) * 2006-11-21 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
US20090053213A1 (en) * 2005-05-18 2009-02-26 Morphosys Ag Anti-Gm-Csf Antibodies and Uses Therefor
WO2010124163A2 (en) * 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE139900T1 (de) * 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
ES2351149T3 (es) 1998-11-09 2011-02-01 Biogen Idec Inc. Anticuerpo quimérico dirigido contra cd20, el rituxan, para uso en el tratamiento de la leucemia linfocítica crónica.
RU2236251C2 (ru) 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
ATE444308T1 (de) 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
MX2007012569A (es) 2005-04-18 2007-12-06 Micromet Ag Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos.
US7601335B2 (en) * 2005-05-20 2009-10-13 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
JP2010527939A (ja) 2007-05-23 2010-08-19 シーアールシー・フォー・アズマ・アンド・エアウェイズ・リミテッド 中和抗体
WO2008153997A1 (en) * 2007-06-07 2008-12-18 Brookwood Pharmaceuticals, Inc. Reduced-mass, long-acting dosage forms
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009062238A1 (en) 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
KR101824512B1 (ko) 2008-04-28 2018-02-02 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
CA2717987C (en) 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
US20100122819A1 (en) 2008-11-17 2010-05-20 Baker Hughes Incorporated Inserts with Swellable Elastomer Seals for Side Pocket Mandrels
MX2011008611A (es) * 2009-02-16 2011-10-21 Biolex Therapeutics Inc Anticuerpos anti-cd20 humanizados y metodos de uso.
AR075982A1 (es) 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053213A1 (en) * 2005-05-18 2009-02-26 Morphosys Ag Anti-Gm-Csf Antibodies and Uses Therefor
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
WO2007092939A2 (en) * 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
WO2008064321A2 (en) * 2006-11-21 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
WO2010124163A2 (en) * 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAKAGAMI T, et al., American Journal of Respiratory and Critical Care Medicine, (2010) Vol 182, pp 49-61 *

Also Published As

Publication number Publication date
JP2014520784A (ja) 2014-08-25
CA2839513A1 (en) 2013-01-10
KR20140061379A (ko) 2014-05-21
RU2013156435A (ru) 2015-08-20
WO2013004806A1 (en) 2013-01-10
CN103827143A (zh) 2014-05-28
BR112013033944A2 (pt) 2017-12-19
AU2012280267A1 (en) 2014-01-16
US20140234298A1 (en) 2014-08-21
EP2729498A1 (en) 2014-05-14
AU2016201736A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
US20140234298A1 (en) Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
JP6486887B2 (ja) 皮下投与される抗ｉｌ−６受容体抗体
JP6013733B2 (ja) Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
US20240366756A1 (en) Combinations and uses thereof
CN102512675A (zh) 用于治疗多发性硬化的方法
KR20120054068A (ko) 벤다무스틴과 어푸코실화된 ｃｄ20 항체의 복합 요법
JP2024533119A5 (enExample)
JP2017519757A (ja) 慢性リンパ球性白血病（ｃｌｌ）の処置
KR20130055660A (ko) 어푸코실화된 cd20 항체와 항-vegf 항체의 복합 요법
US20200237905A1 (en) Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
Gensicke et al. Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis
US20200231666A1 (en) Treatment paradigm
KR20230045613A (ko) Covid-19의 치료 및 예방을 위한 sars-cov-2 항체
KR20250044359A (ko) 항-ccr8 항체 및 사용 방법
US20250257141A1 (en) Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist
US20240270862A1 (en) Use of b cell depleting agents for the treatment of rheumatic heart disease
JP2020055830A (ja) 慢性リンパ球性白血病（ｃｌｌ）の処置

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ THERAPEUTIC COMBINATIONS OF ANTI-CD20 AND ANTI-GM-CSF ANTIBODIES AND USES THEREOF

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired